MilliporeSigma
  • Fluorescent Anti-MUC5AC Brightly Targets Pancreatic Cancer in a Patient-derived Orthotopic Xenograft.

Fluorescent Anti-MUC5AC Brightly Targets Pancreatic Cancer in a Patient-derived Orthotopic Xenograft.

In vivo (Athens, Greece) (2022-01-02)
Michael A Turner, Hannah M Hollandsworth, Hiroto Nishino, Siamak Amirfakhri, Thinzar M Lwin, Andrew M Lowy, Sukhwinder Kaur, Gopalakrishnan Natarajan, Kavita Mallya, Robert M Hoffman, Surinder K Batra, Michael Bouvet
ABSTRACT

Overexpression of mucin-5AC (MUC5AC) makes it a targetable biomarker in pancreatic cancer. The present study evaluated tumor targeting with a MUC5AC antibody conjugated to a near-infrared dye in a patient-derived orthotopic xenograft (PDOX) mouse model. MUC5AC monoclonal antibody was conjugated to the near-infrared dye IRDye800CW to synthesize MUC5AC-IR800. PDOX models were established by implanting a high-MUC5AC-expressing patient-derived pancreatic tumor on the pancreas of nude mice. After 4 weeks of PDOX tumor growth, mice were imaged after receiving MUC5AC-IR800 (75 μg) intravenously. In the PDOX models, MUC5AC-IR800 selectively and brightly targeted the pancreatic tumor (tumor to background ratio: 2.46±0.465). MUC5AC-IR800 provides distinct visualization of pancreatic tumors. MUC5AC-IR800 may be used clinically in the future to improve pancreatic cancer resection. This novel fluorescent probe is also promising for targeting of pre-malignant pancreatic lesions with subsequent resection under fluorescence guidance.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Anti-Mucin MUC5AC Antibody, clone CLH2, clone CLH2, Chemicon®, from mouse